Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers.
adverse events
enzalutamide
mCRPC
talazoparib
treatment management
Journal
Clinical journal of oncology nursing
ISSN: 1538-067X
Titre abrégé: Clin J Oncol Nurs
Pays: United States
ID NLM: 9705336
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
medline:
26
9
2024
pubmed:
26
9
2024
entrez:
26
9
2024
Statut:
ppublish
Résumé
About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC). This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC. This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice. Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.
Sections du résumé
BACKGROUND
BACKGROUND
About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).
OBJECTIVES
OBJECTIVE
This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.
METHODS
METHODS
This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.
FINDINGS
RESULTS
Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.
Identifiants
pubmed: 39324718
doi: 10.1188/24.CJON.483-491
doi:
Substances chimiques
Nitriles
0
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
Benzamides
0
Phthalazines
0
talazoparib
9QHX048FRV
Types de publication
Journal Article
Review
Case Reports
Langues
eng
Sous-ensembles de citation
IM